Efficacy and safety of a millimetre wave medical device for pain neuromodulation in peripheral OA: a crossover randomized trial
Authors' conclusion
In patients with peripheral OA, regular use of this MD significantly reduced in pain (VAS), improved both quality of life (EQ5D-5L) and sleep quality (VAS).
Study context
- Population
- Patients with peripheral OA (ankle, knee, hip, shoulder, elbow, fingers) and pain ≥4 on Visual Analogue Scale (VAS)OFF/ON 31, ON/OFF 29
- Participants
- 60 patients
- Comparison
- Millimetre-wave-emitting medical device use vs no use
- Primary endpoint
- Self-assessed pain
Methodological detailscrossover, monocentric, prospective
- Crossover
- Monocentric
- Prospective
Primary result
As reported in the abstract
Mean daily VAS pain score
MD use
4.57
mean · SD 2
Without MD use
5.32
mean · SD 1.77
- Mean paired difference between periods (SD 1.77), P = 0.002
- 0.74
- Effect size
- 0.42
Secondary outcomes
Quality of life and sleep quality
- Significant improvement with MD use
Safety
Serious adverse events
- None reported
Original publication
Efficacy and safety of a millimetre wave medical device for pain neuromodulation in peripheral OA: a crossover randomized trial. Rheumatology (Oxford). Published 13 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →